Brief: Bioarctic Says Co & Eisai Announced Today That Leqembi Has Been Approved For Treatment Of Alzheimer's Disease In Israel
July 11 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AB - CO & EISAI ANNOUNCED TODAY THAT LEQEMBI HAS
BEEN
APPROVED FOR TREATMENT OF ALZHEIMER'S DISEASE IN ISRAEL
Source text for Eikon: ID:nWkr8hYbDb
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million